[sheet: Cover]

[sheet: Cover]
Field | Value
Document Title | Benchmarking Study — Comparable Company and Transaction Data
Prepared By | Whitmore Valuation Group LLC
Address | 200 Ashbury Asset Advisors, Suite 700, Boston, MA 02109
Lead Economist | Dr. Helena Vasquez, Ph.D., Managing Director
Supporting Economist | Dr. Rohan Chakrabarti, Ph.D., Senior Director
Prepared Under Direction Of | Calderwood & Harkness LLP (Matter No. 1018-00009-KV)
Engagement Partner (C&H) | Leonard Cross, Responsible Partner, Tax
Client | Penterra Pharmaceuticals Corp.
Client EIN | 22-3741856
Subject Entity | Penterra Biopharma International DAC (PBI)
PBI Irish Tax Reference | 3218764T
Tax Years Analyzed | 2017, 2018, 2019, 2020
Date | November 2022
Privileged & Confidential | Prepared at the direction of counsel pursuant to Kovel arrangement (Ref: 1018-00009-KV, dated June 20, 2022). Attorney-Client Privilege / Work Product Doctrine.
Purpose | Identification and analysis of comparable uncontrolled transactions (CUT) for legacy IP royalty rate benchmarking and comparable profits method (CPM) / transactional net margin method (TNMM) analysis for PBI cost-sharing arrangement under IRC § 482, Treas. Reg. §§ 1.482-4 and 1.482-7
IRS Exam Reference | LB&I-NE-TP-2022-00641
[sheet: CUT Search Criteria]
Criterion No. | Screening Parameter | Filter Applied | Rationale
1 | Industry | Pharmaceutical, biotechnology, and specialty therapeutics (SIC 2833–2836; NAICS 325411–325414) | Ensure comparability to PPC's specialty pharma and biotech IP portfolio (oncology, immunology, rare disease)
2 | Agreement Type | Exclusive and semi-exclusive out-licenses of pharmaceutical IP (compound / product rights) | Match the structure of the PPC-PBI legacy IP license (exclusive rights for non-Americas territory)
3 | IP Stage | Approved / marketed products and late-stage clinical compounds | PPC legacy compounds were approved products at the time of the license; pre-clinical and early-stage agreements excluded as non-comparable
4 | Geographic Scope | Territorial licenses (regional / multi-country, excluding global or U.S.-only) | PBI license covers non-Americas territories (EMEA, APAC); global or single-country deals not comparable
5 | Transaction Date | License agreements executed between 2008 and 2018 | Ensure temporal comparability to the PPC-PBI license (legacy compounds licensed from 2012)
6 | Licensee Role | Licensee performs commercialization functions (regulatory, marketing, distribution) | PBI performs regulatory, commercial-strategy, supply-chain, and medical-affairs functions; pure financial licenses excluded
7 | Royalty Base | Net sales-based running royalty (excluding milestone-only or lump-sum agreements) | PPC-PBI royalty is calculated as a percentage of net sales
8 | Data Availability | Publicly available royalty rate data (SEC filings, patent databases, licensing databases) | Verifiability requirement under Treas. Reg. § 1.482-4
9 | Therapeutic Area | Oncology, immunology, autoimmune, rare/orphan disease (preferred but not mandatory) | PPC's legacy compounds are concentrated in oncology and immunology
10 | Exclusions | Related-party transactions, agreements with unusual non-cash consideration, government/academic licenses | Ensure arm's-length comparability per Treas. Reg. § 1.482-1(d)
[sheet: CUT Comparable Agreements]
Comp. No. | Licensor | Licensee | Agreement Date | Therapeutic Area | IP Stage | Licensed Territory | Royalty Rate (%) | Royalty Base | Upfront / Milestone Payments | Licensee Functions | Exclusivity | Term (years) | Comparability Notes
1 | Astraline Therapeutics Inc. | MedBridge Pharma GmbH | 2010-03-15 | Oncology | Approved / Marketed | EMEA | 3.1 | Net Sales | $15M upfront; $25M milestones | Full commercialization: regulatory, marketing, distribution | Exclusive | 12 | Lowest rate in sample; mature product with limited remaining patent life
2 | Celvara Biosciences Ltd. | Kairos Health International AG | 2011-07-22 | Immunology | Approved / Marketed | EMEA + APAC | 3.8 | Net Sales | $20M upfront; $40M milestones | Full commercialization including local clinical trials | Exclusive | 15 | Multi-regional territory comparable to PBI scope
3 | Pinnacle BioPharma Corp. | Novara Medical Holdings S.A. | 2012-01-10 | Oncology | Late-stage (Phase III) + 1 approved | EMEA | 4 | Net Sales | $30M upfront; $50M milestones | Regulatory submissions, marketing, distribution | Exclusive | 10 | Mixed IP stage; approved product dominant
4 | Orionis Pharma Inc. | Thalweg Life Sciences B.V. | 2009-11-05 | Rare Disease / Orphan | Approved / Marketed | EMEA + Latin America (ex-Brazil) | 4.2 | Net Sales | $10M upfront; $15M milestones | Full commercialization and pricing decisions | Exclusive | 14 | Orphan drug with smaller revenue base but comparable functions
5 | Summerfield Drug Development LLC | Rhenania Pharmaceuticals GmbH | 2013-06-18 | Oncology | Approved / Marketed | EMEA | 4.4 | Net Sales | $25M upfront; $35M milestones | Regulatory, marketing, supply chain management | Exclusive | 12 | Median comparable; closely aligned therapeutic area and licensee functions
6 | Hartland Molecular Sciences Inc. | Pacifica Therapeutics Pty Ltd | 2010-09-01 | Immunology / Autoimmune | Approved / Marketed | APAC | 4.5 | Net Sales | $18M upfront; $30M milestones | Full commercialization including local manufacturing coordination | Exclusive | 10 | Rate matches PPC's 4.5%; strong functional comparability
7 | Elmsford Biologics Corp. | Stellaris MedTech S.p.A. | 2014-02-28 | Oncology | Approved / Marketed | EMEA | 4.8 | Net Sales | $35M upfront; $55M milestones | Regulatory, marketing, distribution, and medical affairs | Exclusive | 15 | Higher upfront consideration; rate adjusted for total deal value
8 | Greenvale Research Labs Inc. | Meridian Health Sciences Ltd. | 2012-04-15 | Rare Disease | Approved / Marketed | EMEA + APAC | 5 | Net Sales | $12M upfront; $20M milestones | Full commercialization | Exclusive | 12 | Broad territory; orphan designation
9 | Larkfield Therapeutics LLC | Nordvik Pharma AS | 2011-08-30 | Oncology / Hematology | Approved / Marketed | EMEA + Select APAC | 5.2 | Net Sales | $22M upfront; $45M milestones | Regulatory, marketing, pricing decisions | Exclusive | 11 | Above-median; higher-value oncology compound
10 | Ashbury Pharmaceutical Holdings Inc. | Caspian BioVentures FZ-LLC | 2015-01-20 | Immunology | Late-stage (Phase III) | Middle East + APAC | 5.5 | Net Sales | $8M upfront; $30M milestones | Full commercialization post-approval | Exclusive | 10 | Late-stage IP; higher risk premium reflected in rate
11 | Aldermere & Co. Biotech Inc. | Vistula Pharma Sp. z o.o. | 2013-10-05 | Oncology | Approved / Marketed | Central & Eastern Europe | 5.8 | Net Sales | $14M upfront; $25M milestones | Marketing, distribution, regulatory filings | Exclusive | 8 | Narrower territory; shorter term
12 | Clearwater Lifesciences Corp. | Aravind Therapeutics Pvt Ltd | 2016-03-12 | Rare Disease / Metabolic | Approved / Marketed | India + Southeast Asia | 6.2 | Net Sales | $5M upfront; $15M milestones | Full commercialization including local manufacturing | Exclusive | 12 | Emerging market territory; higher royalty reflects IP value vs. market size
13 | Dunmore Therapeutics Inc. | Halcyon MedGroup AG | 2014-07-25 | Oncology / Immuno-oncology | Approved + Phase II pipeline | EMEA | 6.5 | Net Sales | $40M upfront; $70M milestones | Regulatory, marketing, medical affairs, pricing | Exclusive | 15 | Highest comparable rate within IQR; includes pipeline IP
14 | Fenwick Molecular Corp. | Sakura BioHealth K.K. | 2017-05-10 | Immunology | Approved / Marketed | Japan + APAC | 6.8 | Net Sales | $28M upfront; $50M milestones | Full commercialization; local regulatory and medical affairs | Exclusive | 10 | Upper quartile; single-country anchor (Japan) with APAC expansion rights
[sheet: CUT Statistical Analysis]
Statistic | Royalty Rate (%)
Number of Comparables | 14
Minimum | 3.1
25th Percentile (Q1) | 4.1
Median (Q2) | 4.65
Arithmetic Mean | 4.84
75th Percentile (Q3) | 5.65
Maximum | 6.8
Interquartile Range (IQR) | 4.1% – 5.65%
Full Range | 3.1% – 6.8%
PPC Legacy IP Royalty Rate | 4.5
IRS Proposed Royalty Rate | 11
PPC Rate Within IQR? | Yes — 4.5% falls within the 4.1%–5.65% interquartile range
IRS Rate Within IQR? | No — 11.0% is significantly above the 75th percentile (5.65%)
PPC Rate vs. Median | PPC rate (4.5%) is 0.15 pp below the median (4.65%)
[sheet: CUT Royalty Impact]
Tax Year | Legacy Non-Americas Net Sales ($M) | PPC Royalty Rate (%) | Royalty Paid at 4.5% ($M) | IRS Proposed Rate (%) | Royalty at IRS 11.0% ($M) | Proposed Royalty Adjustment ($M)
2017 | 814.6 | 4.5 | 36.66 | 11 | 89.61 | 52.95
2018 | 762.3 | 4.5 | 34.3 | 11 | 83.85 | 49.55
2019 | 691.8 | 4.5 | 31.13 | 11 | 76.1 | 44.97
2020 | 624.1 | 4.5 | 28.08 | 11 | 68.65 | 40.57
Total | 2892.8 | 130.18 | 318.21 | 188.04
[sheet: CPM-TNMM Search Criteria]
Criterion No. | Screening Parameter | Filter Applied | Rationale
1 | Industry Classification | Pharmaceutical and biotechnology distributors, IP-holding and commercialization entities (SIC 5122, 2830s; NAICS 424210, 325411–325414) | Match PBI's dual function as IP holder and commercialization principal for non-Americas territories
2 | Functional Profile | Companies performing regulatory, marketing, distribution, and/or IP management functions; bearing market and inventory risk | PBI performs regulatory, commercial-strategy, supply-chain, and medical-affairs functions and bears market risk for 68 country markets
3 | Geographic Operations | Companies with primary operations in EMEA and/or APAC | PBI's operations span EMEA and APAC non-Americas territories
4 | Size (Revenue) | Revenue between $200M and $5B (or local currency equivalent) | PBI revenue of €2.14B (FY2020); filter ensures size comparability
5 | Financial Data Availability | At least 4 years of audited financial statements (2017–2020 or overlapping period) | Testing period is TY 2017–2020
6 | Independence | Exclude subsidiaries of large multinational pharma groups where segmental data is not separately reported | Ensure profitability data reflects comparable entity-level economics
7 | Exclusions | Companies with losses in more than one year, companies undergoing restructuring, or companies with material non-operating income | Ensure clean operating margin data for benchmarking
8 | Asset Profile | Companies owning or licensing intangible property (IP) for exploitation in licensed territories | PBI holds IP rights under the CSA and legacy license for non-Americas exploitation